Daxor to Present at the H.C. Wainwright Global Life Sciences Conference
- Daxor Corporation will present at the H.C. Wainwright Global Life Sciences Conference to showcase its accomplishments in financial performance, product commercialization, and research.
- The presentation will highlight new prospective medical trials for the use of Daxor's BVA-100® blood test in critical care, COVID-19, and heart failure management.
- None.
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE: DXR), the global leader in blood volume measurement technology, announces today that President and CEO Michael Feldschuh will present at the H.C. Wainwright Global Life Sciences Conference which is being held from March 9th to 10th through a virtual format with on-demand video presentations.
Mr. Feldschuh will report on the many accomplishments of the Company in the areas of financial performance, commercialization of products, groundbreaking research and product development, and new prospective medical trials for the use of Daxor’s BVA-100® blood test in the management of critical care, COVID-19, and heart failure with leading institutions.
The presentation will be available for on-demand listening beginning at 7:00 AM ET on Tuesday, March 9, 2021 and will be available for 90 days. For those interested in viewing Mr. Feldschuh's presentation, conference registration can be accessed here. Mr. Feldschuh will also be available for virtual one-on-one meetings on March 9-10, and meeting requests can be made once registered.
Event: H.C. Wainwright Global Life Sciences Conference
Date: March 9th -10th
Register here:
https://my.ct.events
Interested investors can contact Bret Shapiro at COREIR either by calling 1-516-222-2560 or emailing brets@coreir.com.
About Daxor Corporation
Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). We developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
FAQ
Who will be presenting at the H.C. Wainwright Global Life Sciences Conference?
What will be discussed during the presentation?
What is the focus of the prospective medical trials?
How long will the presentation be available for on-demand listening?
How can interested investors view the presentation?
Will there be an opportunity for virtual one-on-one meetings?
